{"title":"一名同时服用利伐沙班和藏红花补充剂患者的出血并发症：病例报告。","authors":"Zinat Heidari, Maryam Daei, Hossein Khalili, Amirhossein Sahebkar","doi":"10.2174/1871529X22666220418102545","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Direct oral anticoagulants (DOACs) carry a lower potential risk of food/herb and drug interactions compared with oral vitamin K antagonists. However, as a new class of medications, drug interactions of DOACs have not been fully known.</p><p><strong>Case presentation: </strong>We herein present the case of a 64-year old male with the complaint of acute onset epistaxis and bleeding gums following the concomitant use of rivaroxaban and saffron supplement. It seems that coadministration of DOACs and saffron supplements should be avoided due to the potential drug-herbal interactions and possible risk of subsequent bleeding complications.</p><p><strong>Conclusion: </strong>However, further larger scale surveillance studies are needed to confirm the findings and assess the clinical significance.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bleeding Complication in a Patient with Concomitant Use of Rivaroxaban and Saffron Supplement: a Case Report.\",\"authors\":\"Zinat Heidari, Maryam Daei, Hossein Khalili, Amirhossein Sahebkar\",\"doi\":\"10.2174/1871529X22666220418102545\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Direct oral anticoagulants (DOACs) carry a lower potential risk of food/herb and drug interactions compared with oral vitamin K antagonists. However, as a new class of medications, drug interactions of DOACs have not been fully known.</p><p><strong>Case presentation: </strong>We herein present the case of a 64-year old male with the complaint of acute onset epistaxis and bleeding gums following the concomitant use of rivaroxaban and saffron supplement. It seems that coadministration of DOACs and saffron supplements should be avoided due to the potential drug-herbal interactions and possible risk of subsequent bleeding complications.</p><p><strong>Conclusion: </strong>However, further larger scale surveillance studies are needed to confirm the findings and assess the clinical significance.</p>\",\"PeriodicalId\":93925,\"journal\":{\"name\":\"Cardiovascular & hematological disorders drug targets\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-04-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiovascular & hematological disorders drug targets\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1871529X22666220418102545\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular & hematological disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871529X22666220418102545","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景：与口服维生素 K 拮抗剂相比，直接口服抗凝剂（DOAC）发生食物/草药和药物相互作用的潜在风险较低。然而，作为一类新药，DOACs 的药物相互作用尚未完全为人所知：我们在此介绍一例 64 岁男性患者的病例，患者主诉在同时服用利伐沙班和藏红花补充剂后出现急性鼻衄和牙龈出血。由于潜在的药物与草药之间的相互作用以及随后可能出现出血并发症的风险，似乎应避免同时服用 DOACs 和藏红花补充剂：然而，还需要进一步开展更大规模的监测研究，以确认研究结果并评估其临床意义。
Bleeding Complication in a Patient with Concomitant Use of Rivaroxaban and Saffron Supplement: a Case Report.
Background: Direct oral anticoagulants (DOACs) carry a lower potential risk of food/herb and drug interactions compared with oral vitamin K antagonists. However, as a new class of medications, drug interactions of DOACs have not been fully known.
Case presentation: We herein present the case of a 64-year old male with the complaint of acute onset epistaxis and bleeding gums following the concomitant use of rivaroxaban and saffron supplement. It seems that coadministration of DOACs and saffron supplements should be avoided due to the potential drug-herbal interactions and possible risk of subsequent bleeding complications.
Conclusion: However, further larger scale surveillance studies are needed to confirm the findings and assess the clinical significance.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
